• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For CeriBell Stock Could Change Following Raised Revenue Guidance

    Simply Wall St·11/10/2026 13:19:44
    Listen to the news
    • CeriBell raised its 2026 revenue outlook to US$115 million to US$117 million, reported higher quarterly and year to date revenue, and continues to run at a sizeable net loss as it scales its point of care EEG platform.
    • The commercial launch of CeriBell’s AI powered delirium monitoring solution, backed by a new Medicare add on payment, adds a fresh use case on the same hardware without yet being counted in the updated revenue guidance.
    • The next focus will be on how CeriBell’s raised guidance and delirium launch reshape the existing investment narrative around the platform.
    Capitalize on the momentum around CeriBell’s AI driven delirium launch by scanning a hand picked set of healthcare AI peers in the 36 healthcare AI stocks.

    CeriBell Investment Narrative Recap

    To hold CeriBell, you need to believe the point of care EEG platform can keep expanding into more hospitals and use cases while gradually narrowing losses. The raised 2026 revenue outlook to US$115 million to US$117 million supports the analyst consensus narrative on Simply Wall St that expects strong top line growth, but the story still hinges on scaling utilization efficiently.

    The biggest near term catalyst is whether higher guidance translates into visible operating leverage, since CeriBell reported a third quarter net loss of US$21.35 million and a nine month loss of US$60.36 million. The largest risk remains that operating expenses and cash burn stay elevated, which could extend the timeline to breakeven.

    The delirium monitoring launch is the announcement most tied to this earnings and guidance update. It adds a second major indication on the same hardware in an ICU population where delirium affects an estimated 30% of patients and often goes under detected with current bedside assessments.

    For you, the key question is whether CeriBell can turn this into a real commercial driver without overextending the cost base. Execution risk is meaningful. The business now needs to educate clinicians, prove workflow fit, and convert the New Technology Add on Payment of up to US$2,171 per eligible Medicare case into steady demand that supports the broader growth narrative.

    CeriBell's current earnings are a loss of US$66.0 million, with analysts expecting this to shift to earnings of US$26.7 million on forecast revenue of US$208.6 million by 2029. That outlook assumes revenue grows 26.9% a year and implies an earnings swing of about US$92.7 million from today's level.

    Uncover how CeriBell's fair value indicates a 7% potential upside to its current price that could narrow quickly if CeriBell executes on its plan.

    NasdaqGS:CBLL 1-Year Stock Price Chart
    NasdaqGS:CBLL 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community cluster in a tight US$29.57 to US$31.57 band, which limits any outlier read on CeriBell’s pricing. You are still weighing that against widening losses, heavy EEG rollout spending, and the open question of how quickly delirium and future indications translate into meaningful commercial traction. Opinions can differ sharply, so it is worth reviewing several of these community viewpoints directly.

    Explore another CeriBell fair value estimate, including one that suggests it could be worth just $29.57.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond CeriBell?

    If CeriBell has sharpened your interest in healthcare and high growth stories, it can help to compare it with a wider watchlist built around clear, data driven criteria.